Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review by Bassendine, Margaret F. & Bridge, Simon
Northumbria Research Link
Citation:  Bassendine,  Margaret  F.  and  Bridge,  Simon  (2020)  Relapse  of  polymyalgia  rheumatica 
following adjuvanted influenza vaccine: A case-based review. European Journal of Rheumatology, 7 
(1). pp. 37-40. ISSN 2147-9720 
Published by: Medical Research and Education Association
URL: https://doi.org/10.5152/eurjrheum.2019.19152 <https://doi.org/10.5152/eurjrheum.2019.19152>
This version was downloaded from Northumbria Research Link: http://nrl.northumbria.ac.uk/42580/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)
                        
DOI: 10.5152/eurjrheum.2019.19152
Relapse of polymyalgia rheumatica following 
adjuvanted influenza vaccine: A case-based review
Introduction
Polymyalgia rheumatica (PMR) is a common inflammatory joint disease in older individuals, associated with 
increases in serum acute phase reactants. Imaging techniques have highlighted the presence of bursitis 
in the majority and vasculitis in some, in keeping with the overlap with giant cell arteritis (GCA) (1). Rapid 
symptomatic relief is obtained with prednisolone, but relapses are common when the steroid dose is re-
duced. The etiology and pathogenesis of PMR remain obscure. Both genetic predisposition and environ-
mental triggers are thought to play a role, but most research has explored the immunological aspects of 
the disease. Recently, it has been shown that the distribution of B cells is highly disturbed in PMR and GCA, 
and that B cells likely contribute to the enhanced interleukin-6 response seen in both diseases (2). 
Immunization has been reported as a rare trigger for vasculitides; a recent review of 1797 adverse events (AEs) 
reported across three international databases found that PMR represented 9.2% of reported AEs and was 
more frequently associated with influenza vaccines (3). In a review of 21 cases of GCA/PMR developing within 
3 months of influenza vaccination, the role that adjuvant or influenza virus antigen plays in triggering disease 
is discussed (4). Recently, one case of PMR has been described following influenza B infection (5).
Seasonal influenza infection is an important cause of death in older individuals. Recent data from Europe 
for 2016/2017 confirm that excess mortality, especially in people aged >65 years, was primarily explained 
by the circulation of influenza virus A (H3N2) (6). Indeed, seasonal epidemics of influenza can cause up to 
5 million infections and 250,000-650,000 deaths annually, from not only respiratory illness but also acute 
myocardial infarction (7) and other complications. Vaccination is the most effective intervention to prevent 
influenza and its associated morbidity and mortality and hence is recommended annually, especially in 
high-risk individuals. In the United Kingdom, uptake and effectiveness of influenza vaccination in seasons 
from 2010/2011 to 2016/2017 was high in people aged >65 years, with 80% of the >75 years receiving the 
vaccine (8). 
Influenza viruses are enveloped negative-sense, single-stranded, segmented RNA viruses that belong to 
the family Orthomyxoviridae and are grouped into four strains (A, B, C, and D). Only influenza strains A and 




Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatological condition affect-
ing individuals aged >50 years. There have been rare reports of PMR and other vasculitides devel-
oping within 3 months of influenza vaccination. Influenza is a major public health issue associated 
with seasonal increased mortality and intensified health care service use. Annual vaccination is the 
most effective intervention to prevent influenza, especially in elderly individuals. We report a severe 
“flare” of PMR in a 70-year-old patient after receiving the adjuvanted trivalent influenza vaccine, as 
recommended by the Joint Committee on Vaccination and Immunisations for this age group in the 
UK National Health Service in 2018-2019. The adverse event (AE) could be interpreted as the newly 
described autoimmune/inflammatory syndrome induced by adjuvants (ASIA syndrome) as both PMR 
and ASIA display hyperactive immune responses. Caution is warranted in the use of vaccine adjuvants 
in patients with PMR with pre-existing imbalance of B and T cell homeostasis. Rare AEs are important 
to individuals, and personalized medicine means we should move away from “one size fits all” for 
vaccines, as well as for therapeutics. 
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B cause seasonal infections in humans. The vi-
ral envelope contains two major glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA), 
and currently, the hemagglutination inhibition 
antibody (Ab) titre is regarded as the best avail-
able parameter for predicting protection from 
influenza infection. Unfortunately, Ab respons-
es and the protection elicited by available vac-
cines tend to be lower in older than in younger 
adults (9). This has led to the development of 
vaccines containing adjuvants which trigger 
a strong immune response at lower antigen 
doses (10); this is helpful not only in the elder-
ly but also in the public health situation of a 
threatened epidemic/pandemic. One vaccine 
adjuvant MF59® (Novartis International AG, 
Basel, Switzerland) is a squalene-based oil-in-
water emulsion that has been used in several 
registered pandemic and seasonal influenza 
vaccines since 1997. It has greater efficacy than 
non-adjuvanted vaccines, especially in reduc-
ing hospitalizations due to influenza-related 
complications (11). Hence in the UK, the Joint 
Committee on Vaccinations and Immunisa-
tions advised in October 2017 that FLUAD, an 
influenza vaccine containing MF59®, and HA 
should be used for the >65 years rather than 
non-adjuvanted vaccines. We describe a pa-
tient with PMR in whom this adjuvanted in-
fluenza vaccine preparation triggered a severe 
flare-up of disease and discuss the role of the 
adjuvant MF59®.
Case Presentation
A 65-year-old female presented in 2013 with 
pain and stiffness in her neck, girdle joints, and 
knees, particularly her left knee, preceded by 
“flu-like” symptoms (dry cough and headache) 
during a trip to New South Wales, Australia. 
She recalled multiple mosquito bites, so the 
possibility of Ross River fever, the most com-
mon mosquito-borne disease in Australia, was 
considered. It is caused by an arthritogenic 
alphavirus, Ross River virus (RRV), and leads to 
debilitating musculoskeletal inflammatory dis-
ease that usually resolves in 3-6 months (12). 
Treatment is supportive, but her symptoms 
worsened despite “over the counter” non-ste-
roidal anti-inflammatory medication. Her pain 
peaked in the mornings so that it became dif-
ficult to function before midday. She attended 
a general practitioner (GP) when blood tests 
revealed an elevated erythrocyte sedimen-
tation rate (ESR) of 120 mm/h (normal <21 
mm/h) and C-reactive protein (CRP) of 141.7 
mg/L (normal <3.0 mg/L), decreased albumin 
of 31 g/L (normal 35-50 g/L), and high normal 
globulin fraction of 39 g/L (normal 20-39 g/L). 
Negative results were obtained for rheumatoid 
factor, antinuclear Ab, RRV IgG and IgM Ab, Bar-
mah Forest virus (another alphavirus causing 
musculoskeletal disease) IgG and IgM Ab, and 
urinary Bence Jones protein. 
In view of these results showing activation of 
the inflammatory cascade (13) and a family his-
tory of PMR (her father), she was commenced 
on prednisolone 15 mg daily according to the 
guidelines of the Royal College of Physicians, 
London. After just 3 days of prednisolone, she 
was reviewed by a rheumatology specialist in 
Sydney when she was already symptomatical-
ly improved, and repeat blood tests reflected 
this with an ESR of 90 mm/h and a CRP of 71.4 
mg/L. Serum protein electrophoresis showed 
an increased alpha-1 globulin of 4.0 g/L (nor-
mal 0.3-2.0 g/L), alpha-2 globulin of 12.0 g/L 
(normal 4.0-8.5 g/L), and beta globulin of 10.0 
g/L (normal 5.0-9.5 g/L) with no paraprotein 
detected on serum electrophoresis. Additional 
tests showed negative cyclic citrullinated pep-
tide and neutrophil cytoplasmic antibody an-
tibodies. After 6 weeks of prednisolone 15 mg 
daily, she was clinically 95% better, and her CRP 
was 3.3 mg/L. On follow-up, prednisolone dose 
was gradually reduced from 15 mg to 6 mg 
over 9 months in 2013. In the early 2014, she 
developed focal distal interphalangeal joint ar-
thritis associated with some diurnal PMR symp-
toms so the glucocorticoid (GC) dose was tem-
porarily increased to 7.5 mg daily. Since 2015, 
her GC dose has always been <5 mg daily and 
was maintained at 3/2.5 mg on alternate days 
for most of 2017/2018. Although her disease 
was in remission with normal ESR and CRP 
levels, attempts to discontinue steroids were 
unsuccessful owing to mild symptoms in the 
mornings.
The patient’s influenza vaccination history 
over five decades of adulthood has proven to 
be difficult to ascertain accurately. As a health 
care professional working in a high-risk area for 
the last 20 years of her career, she followed UK 
public health advice and received influenza 
vaccination annually via her National Health 
Service employer. In addition to >20 influenza 
vaccinations over her working life, she had also 
received the adjuvant keyhole limpet hemo-
cyanin (KLH), a large T lymphocyte dependent 
immunostimulating protein, when she volun-
teered in a study on the primary, secondary, 
and tertiary immune responses of normal indi-
viduals to KLH (14). The influenza vaccines that 
the patient received after commencing GC for 
her PMR are the following:
· 2015 Intanza-trivalent, split virion, inactivat-
ed virus (Sanofi Pasteur MSD) (on predniso-
lone 5 mg daily).
· 2016 Fluarix Tetra-quadrivalent, split virion, 
inactivated virus (GSK) (on prednisolone 3.5 
mg daily). 
· 2017 FluQuadri-quadrivalent split virion, in-
activated virus (Sanofi Pasteur) (on prednis-
olone 3.0 mg daily). 
· 2018 Fluad-adjuvanted trivalent vaccine, 
each 0.5 mL intramuscular injection con-
tains at least 15 µg of HA (Seqirus) (on pred-
nisolone 3.0/2.5 mg alt die).
After the vaccination in October 2018, she de-
veloped the usual local side effects but soon 
began to feel fatigue, myalgia, and arthralgia, 
particularly in her left knee, the predominant 
site of her debilitating severe pain at presen-
tation of her PMR >5 years previously. She in-
creased her daily steroid dose to 4-5 mg on al-
ternate days, and at consultant review 2 weeks 
later, her ESR and CRP levels were normal. She 
hence pursued “self-help” with physiotherapy 
and exercise. Over the next 6 weeks, she dete-
riorated, and her left knee in particular became 
increasingly painful and swollen so that routine 
activities (e.g., getting out of the bath or down 
the stairs, gardening, cleaning, or driving her 
manual car) became very difficult, especially 
in the mornings. Indeed, mornings were spent 
attempting to get started on the day; she felt 
91 not 71 years old. Two months after receiv-
ing FLUAD, she was convinced that the vacci-
nation had caused a flare of her PMR, and she 
increased her GC dosage to 10 mg daily. Within 
a week, she was 70% improved. She was re-
viewed by her GP and specialist who reported 
the reaction to the Vaccine Adverse Event Re-
porting System (www.vaers.hhs.gov) and, via 
the yellow card system, to the Medicines and 
Healthcare products Regulatory Agency, UK. 
Eight months after the dose of prednisolone 
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Main Points
• PMR is a heterogeneous condition which 
overlaps with GCA. We describe a female 
patient who presented with severe 
acute PMR (CRP 141.7 mg/L) who was in 
remission on low-dose prednisolone but 
experienced a significant relapse after 
adjuvanted influenza vaccination.
• The patient, a health care worker, had 
previously received multiple annual 
non-adjuvanted influenza vaccines, im-
plicating the vaccine adjuvant in her 
disease flare. Her symptoms could be 
interpeted as ASIA syndrome. 
• Caution is warranted in the use of vac-
cine adjuvants in patients with PMR who 
have pre-existing imbalance of B and T 
cell homeostasis.
• Rare AEs are important to individuals, 
and personalized medicine means we 
should move away from “one size fits all” 
in vaccines, as well as in therapeutics. 
was increased, she had weaned the dose back 
down to 5 mg daily which is still higher than 
her previous maintenance dose.
Discussion
The AE following influenza vaccination in this 
case is compatible with the rare cases of PMR 
developing within 3 months of vaccination 
previously reported (4). However, in view of the 
extensive influenza vaccination history in this 
health care worker, it is likely that the adjuvant 
component of the vaccine was responsible for 
the severe symptomatic relapse of her PMR. 
The adjuvant in FLUAD is MF59®; it contains 10 
mg of squalene per dose. Squalene is a natural-
ly occurring substance found in plants and an-
imals. It is a cholesterol precursor and obtained 
for commercial purposes primarily from shark 
liver oil. Over 22 million doses of squalene-con-
taining influenza vaccines have been adminis-
tered, and the safety of an MF59®-adjuvanted 
vaccine is well established through a large 
safety database (15). An alarm was raised 
when antibodies to squalene were detected 
in the blood of most patients affected by the 
chronic multisystem illness termed “Gulf War 
syndrome,” but no significant association was 
subsequently found (16). However, a single 
intradermal injection of squalene can induce 
a chronic T cell-mediated arthritis in certain 
strains of rodents (17). The dependence of this 
animal model on CD4+ T cells suggested a role 
for genes within the major histocompatibility 
complex. Arthritis transfer experiments con-
firmed the importance of T cells, particularly 
CD4+ cells in inducing joint inflammation (18). 
In 2011, a new syndrome termed “autoim-
mune/inflammatory syndrome induced by 
adjuvants” (ASIA) was defined (19). ASIA syn-
drome is associated with individual genetic 
predisposition and results from exposure to 
factors triggering hyperactive immune re-
sponses. A number of animal models of sys-
temic and organ specific “autoimmune” dis-
eases induced by adjuvants provide a proof 
of concept (20). In a descriptive analysis of 300 
cases in the international ASIA syndrome reg-
istry, arthralgia, myalgia, and chronic fatigue 
were the most frequently reported symptoms. 
Eighty-nine percent of patients were also diag-
nosed with another defined rheumatic/auto-
immune condition (21). Further analysis of 500 
cases confirmed that polygenic autoinflamma-
tory diseases were significantly associated with 
exposure to influenza vaccination (odds ratio 
10.98, 95% confidence interval 3.81-31.67), 
p<0.0001) (22). Although our patient interpret-
ed her symptoms of arthritis/bursitis, myalgia, 
and fatigue as a “flare” of her PMR, it remains 
possible that it could be interpreted as ASIA 
syndrome as both display hyperactive immune 
responses. 
In a study of patients with primary Sjögren’s syn-
drome vaccinated twice with the squalene-ad-
juvanted inactivated split-virion H1N1 vaccine 
Pandemrix (GlaxoSmithKline, Brentford, UK), it 
was found that patients not only developed 
higher H1N1 IgG titers of greater avidity than 
healthy controls on vaccination, but off-tar-
get B cells were also triggered resulting in in-
creased autoantibody titers (23). The authors 
concluded that “caution is warranted when 
considering vaccination in non-treated auto-
immune patients.” 
Autoantibodies have been reported in patients 
with PMR/GCA against a broad spectrum of 
human autoantigens (24). Recently, an as-
sociation between PMR/GCA and IgG auto-
antibodies against the N-terminal 27 amino 
acids of human ferritin heavy chain has been 
found; these were present in 92% of patients 
before initiation of treatment and 69% of pa-
tients with disease flares compared with 1% of 
healthy blood donors (25). 
Adjuvants, such as squalene, may trigger 
off-target B cells by increasing the frequency 
of T follicular helper cells (26). Patients with un-
treated PMR already have activated dendritic 
cells and monocytes/macrophages, disturbed 
B cell homeostasis (2), and a significant change 
in the Th17 cell to Treg cell ratio that is skewed 
toward an increased Th17 cell response (27). 
Although this disturbed B and T cell homeo-
stasis in PMR is corrected by prednisolone, it 
may be that the low maintenance GC dose in 
this case was inadequate to prevent off-target 
effects of the adjuvant, which the patient be-
lieves triggered her relapse. 
One influenza vaccine is not the same as anoth-
er, in terms of not only efficacy but also safety 
profile. For example, there is now consensus 
that the AS03-adjuvanted influenza vaccine is 
associated with an increased risk of narcolep-
sy (28). Future vaccines with novel adjuvants 
may lead to different AEs, and post marketing 
surveillance needs to be improved (29). In ad-
dition, emerging evidence suggests that the 
repeated influenza vaccinations given to this 
patient may not be favorable for the induction 
and quality of cellular responses which play a 
considerable role in cross-protective immunity 
to different influenza strains (30). The descrip-
tion of ASIA syndrome should prompt research 
into mechanisms and lead to personalized 
medicine in the field of vaccination. There is 
individual variation in immune responses to 
vaccines and adjuvants, and rare AEs are im-
portant to individuals. Patient choice needs to 
be respected; the approach should not be “one 
size fits all” for those aged >65 years.  
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